RASSF1A hypermethylation was detected in 29 out of 45 (64%) primary adenocarcinomas, 10 out of 12 (83%) endocrine tumors, and 8 out of 18 (44%) pancreatitis samples [25]. This evidence concerns the gene RASSF1 and adenocarcinoma.